Valneva
Austria - ViennaBiotechnology
Focus: Valneva is an Austria-based biotechnology company specializing in biologics manufacturing with a focus on infectious diseases and vaccines. The company operates as a mid-cap biotech with a diversified pipeline spanning multiple viral indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
3+3 this month
Stable — net +3 jobs in 30d
8 added, 5 removed. Backfill posture.
Should You Work at Valneva?
AI assessmentValneva offers compelling late-stage pipeline exposure in vaccines and infectious diseases, but lack of active hiring and opaque financials warrant careful due diligence before committing.
Why Work Here
- Strong pipeline depth with 11 Phase 3 programs across high-impact infectious disease areas (Chikungunya, Japanese Encephalitis, COVID-19, Lyme disease) offering exposure to late-stage drug development
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
22 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
IXIARO®
Stable
Peak
Marketed Phase 4 product representing approved revenue base for the company.
Pipeline & Clinical Trials
Help build intelligence for Valneva
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.